Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-18T18:39:23.210Z Has data issue: false hasContentIssue false
  • English
  • Français

Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia

Published online by Cambridge University Press:  22 February 2013

Anto P. Rajkumar ,
B. Poonkuzhali ,
Anju Kuruvilla ,
Alok Srivastava ,
Molly Jacob  and
K. S. Jacob
Anto P. Rajkumar*
Affiliation:
Department of Psychiatry, Christian Medical College, Vellore 632002, India Center for Psychiatric Research, Aarhus University Hospital, Risskov-8240, Denmark
B. Poonkuzhali
Affiliation:
Department of Haematology, Christian Medical College, Vellore 632002, India
Anju Kuruvilla
Affiliation:
Department of Psychiatry, Christian Medical College, Vellore 632002, India
Alok Srivastava
Affiliation:
Department of Haematology, Christian Medical College, Vellore 632002, India
Molly Jacob
Affiliation:
Department of Biochemistry, Christian Medical College, Vellore 632002, India
K. S. Jacob
Affiliation:
Department of Psychiatry, Christian Medical College, Vellore 632002, India
*
Dr Anto Praveen Rajkumar Rajamani, Centre for Psychiatric Research, Aarhus University Hospital, 2, Skovagervej, Risskov-8240, Denmark. Tel: +45 7789 3548; Fax: +45 8612 3173; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

Despite clozapine's superior clinical efficacy in treatment-resistant schizophrenia (TRS), its adverse effects, need for periodic leukocyte monitoring, cost and variable clinical outcomes mandate a clinical need to predict its treatment response. Although cytochrome P450 1A2 (CYP1A2) is the principal determinant of metabolism of clozapine, the role of CYP1A2 gene in the clinical response to clozapine is uncertain. Hence, we investigated its association with treatment responses and adverse events of clozapine in TRS.

Methods

We evaluated four single nucleotide polymorphisms (SNP) in the CYP1A2 gene, clinical responses and serum clozapine levels in 101 consecutive patients with TRS on stable doses of clozapine. We defined clozapine response a priori and investigated allelic and genotypic associations. We assessed the socio-demographic and clinical profiles, premorbid adjustment, traumatic life events, cognition and disability of the participants, using standard assessment schedules for appropriate multivariate analyses.

Results

Our results revealed that CYP1A2 gene SNP (*1C, *1D, *1E and *1F) were not associated with clozapine treatment response, adverse effects, serum clozapine levels or with disability (p values > 0.10).

Conclusion

As CYP1A2 gene SNP do not help to predict the clinical response to clozapine, routine screening for them prior to start clozapine is currently unwarranted. We suggest future longitudinal genome-wide association studies investigating clinical and pharmacogenetic variables together.

Keywords

clozapinecytochrome P-450 CYP1A2pharmacogeneticssingle nucleotide polymorphism
Type
Original Articles
Information
Acta Neuropsychiatrica , Volume 25 , Issue 1 , February 2013 , pp. 2 - 11
Copyright
Scandinavian College of Neuropsychopharmacology 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Kane, J, Honigfeld, G, Singer, J, Meltzer, H.Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789–796.Google Scholar
2Horacek, J, Bubenikova-Valesova, V, Kopecek, Met al.Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20: 389–409.CrossRefGoogle ScholarPubMed
3Meltzer, HY, Alphs, L, Green, AIet al.Clozapine treatment for suicidality in schizophrenia: International suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60:82–91.Google Scholar
4Tandon, R, Fleischhacker, WW.Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 2005;79:145–155.Google Scholar
5Remington, G, Saha, A, Chong, SA, Shammi, C.Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005;19:843–872.Google Scholar
6Henderson, DC, Cagliero, E, Gray, Cet al.Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000;157:975–981.Google Scholar
7Chung, C, Remington, G.Predictors and markers of clozapine response. Psychopharmacology (Berl) 2005;179: 317–335.CrossRefGoogle ScholarPubMed
8Pirmohamed, M, Williams, D, Madden, S, Templeton, E, Park, BK.Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272: 984–990.Google Scholar
9Ozdemir, V, Kalow, W, Okey, ABet al.Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C–>A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine J Clin Psychopharmacol 2001;21:603–607.CrossRefGoogle Scholar
10Eap, CB, Bender, S, Jaquenoud Sirot, Eet al.Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004;24:214–219.Google Scholar
11Djordjevic, N, Ghotbi, R, Jankovic, S, Aklillu, E.Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C>A polymorphism. Eur J Clin Pharmacol 2010;66:697–703.CrossRefGoogle Scholar
12Potkin, SG, Bera, R, Gulasekaram, Bet al.Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl. B):133–136.Google Scholar
13Kronig, MH, Munne, RA, Szymanski, Set al.Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152: 179–182.Google Scholar
14Miller, DD, Fleming, F, Holman, TL, Perry, PJ.Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl. B): 117–121.Google Scholar
15Corchero, J, Pimprale, S, Kimura, S, Gonzalez, FJ.Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 2001;11:1–6.Google Scholar
16Zhou, SF, Wang, B, Yang, LP, Liu, JP.Structure function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010;42:268–354.Google Scholar
17Murayama, N, Soyama, A, Saito, Yet al.Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004;308:300–306.Google Scholar
18Soyama, A, Saito, Y, Hanioka, Net al.Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005;20:24–33.Google Scholar
19Sachse, C, Bhambra, U, Smith, Get al.Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55:68–76.CrossRefGoogle ScholarPubMed
20Arranz, MJ, Munro, J, Sham, Pet al.Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998;32:93–99.Google Scholar
21Souza, RP, de Luca, V, Meltzer, HY, Lieberman, JA, Kennedy, JL.Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. Pharmacogenet Genomics 2010;20:274–276.Google Scholar
22Honigfeld, G, Patin, J.Predictors of response to clozapine therapy. Psychopharmacology (Berl) 1989;99(Suppl): S64–S67.Google Scholar
23Honer, WG, Macewan, GW, Kopala, Let al.A clinical study of clozapine treatment and predictors of response in a Canadian sample. Can J Psychiatry 1995;40:208–211.Google Scholar
24Umbricht, DS, Wirshing, WC, Wirshing, DAet al.Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63:420–424.Google Scholar
25Lieberman, JA, Safferman, AZ, Pollack, Set al.Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744–1752.Google Scholar
26Mancama, D, Arranz, MJ, Kerwin, RW.Genetic predictors of therapeutic response to clozapine: current status of research. CNS Drugs 2002;16:317–324.Google Scholar
27Arranz, MJ, Munro, J, Birkett, Jet al.Pharmacogenetic prediction of clozapine response. Lancet 2000;355: 1615–1616.CrossRefGoogle ScholarPubMed
28Hwang, R, Shinkai, T, De Luca, Vet al.Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology (Berl) 2005;181:179–187.Google Scholar
29Lieberman, JA, Kane, JM, Safferman, AZet al.Predictors of response to clozapine. J Clin Psychiatry 1994;55(Suppl. B):126–128.Google Scholar
30Gross, A, Joutsiniemi, SL, Rimon, R, Appelber, GB.Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study. Pharmacopsychiatry 2004;37:119–122.Google Scholar
31Swen, JJ, Nijenhuis, M, de Boer, Aet al.Pharmacogenetics: from bench to byte–an update of guidelines. Clin Pharmacol Ther 2011;89:662–673.Google Scholar
32Kootstra-Ros, JE, Smallegoor, W, Van der Weide, J.The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 2005;42:216–219.Google Scholar
33Jaquenoud Sirot, E, Knezevic, B, Morena, GPet al.ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009;29:319–326.Google Scholar
34Van der Weide, J, Steijns, LS, Van Weelden, MJ.The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003;13:169–172.CrossRefGoogle ScholarPubMed
35Schulte, PF.Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacother 2006;40:683–688.Google Scholar
36NOVARTIS. Clozaril prescribing information, 2010. URL http://www.pharma.us.novartis.com/product/pi/pdf/Clozaril.pdf [accessed on 2 November 2011].Google Scholar
37APA. Diagnostic and statistical manual of mental disorders. 4th edn. Text Revision (DSM-IV-TR). Washington D.C.: American Psychiatric Association, 2000.Google Scholar
38Overall, JE, Gorham, DR.The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.Google Scholar
39Guy, W.ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education and Welfare, 1976.Google Scholar
40Mioshi, E, Dawson, K, Mitchell, J, Arnold, R, Hodges, JR.The Addenbrooke's Cognitive Examination Revised (ACE-R): a brief cognitive test battery for dementia screening. Int J Geriatr Psychiatry 2006;21:1078–1085.Google Scholar
41WHO. WHODAS II Disability Assessment Schedule: 12-Item interviewer administered version. Geneva: World Health Organization, 2001.Google Scholar
42Pennebaker, JW, Susman, JR.Disclosure of traumas and psychosomatic processes. Soc Sci Med 1988;26:327–332.Google Scholar
43Rabinowitz, J, Levine, SZ, Brill, N, Bromet, EJ.The premorbid adjustment scale structured interview (PAS-SI): preliminary findings. Schizophr Res 2007;90:255–257.Google Scholar
44Wongsinsup, C, Taesotikul, W, Kaewvichit, S, Sangsrijan, S, Sangsrija, S.Determination of clozapine in human plasma by high – performance liquid chromatography with UV – VIS Detector. CMU J Nat Sci 2010;9:29–37.Google Scholar
45Conley, RR, Carpenter, WT Jr, Tamminga, CA.Time to clozapine response in a standardized trial. Am J Psychiatry 1997;154:1243–1247.Google Scholar
46Buckley, P, Miller, A, Olsen, J, Garver, D, Miller, DD, Csernansky, J.When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001;27:615–628.CrossRefGoogle ScholarPubMed
47Gauderman, WJ.Sample size requirements for association studies of gene-gene interaction. Am J Epidemiol 2002;155:478–484.Google Scholar
48Purcell, S, Neale, B, Todd-Brown, Ket al.PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559–575.Google Scholar
49Semiz, UB, Cetin, M, Basoglu, Cet al.Clinical predictors of therapeutic response to clozapine in a sample of Turkish patients with treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1330–1336.Google Scholar
50NCBI-SNP. Reference SNP cluster report: rs762551. Bethesda (MD): National Library of Medicine (US), 2011. URL http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=762551 [accessed on 26 September 2011].Google Scholar
51NCBI-SNP. Reference SNP cluster report: rs35694136. Bethesda (MD): National Library of Medicine (US); 2011. URL http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=35694136 [accessed on 26 September 2011].Google Scholar
52Estellat, C, Torgerson, DJ, Ravaud, P.How to perform a critical analysis of a randomised controlled trial. Best Pract Res Clin Rheumatol 2009;23:291–303.Google Scholar
53Burns, T.Evolution of outcome measures in schizophrenia. Br J Psychiatry Suppl 2007;50:s1–s6.Google Scholar
54Tiwari, AK, Deshpande, SN, Lerer, B, Nimgaonkar, VL, Thelma, BK.Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism Pharmacogenomics J 2007;7:305–311.Google Scholar
55Perry, PJ, Bever, KA, Arndt, S, Combs, MD.Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998;44: 733–738.Google Scholar
56Dratcu, L, Grandison, A, Mckay, G, Bamidele, A, Vasudevan, V.Clozapine-resistant psychosis, smoking, and caffeine: managing the neglected effects of substances that our patients consume every day. Am J Ther 2007;14:314–318.Google Scholar
57Mcevoy, JP, Freudenreich, O, Wilson, WH.Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125–129.Google Scholar
58de Leon, J, Arranz, MJ, Ruano, G.Pharmacogenetic testing in psychiatry: a review of features and clinical realities. Clin Lab Med 2008;28:599–617.Google Scholar
59NCBI-SNP. Reference SNP cluster report: rs2069526. Bethesda (MD): National Library of Medicine (US), 2011. URL http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2069526 [accessed on 26 September 2011].Google Scholar
60NCBI-SNP. Reference SNP cluster report: rs2069514. Bethesda (MD): National Library of Medicine (US), 2011. URL http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2069514 [accessed on 26 September 2011].Google Scholar
61Stefansson, H, Ophoff, RA, Steinberg, Set al.Common variants conferring risk of schizophrenia. Nature 2009;460:744–747.Google Scholar
62Sullivan, PF, Kendler, KS, Neale, MC.Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187–1192.Google Scholar
63Prasad, S, Semwal, P, Deshpande, S, Bhatia, T, Nimgaonkar, VL, Thelma, BK.Molecular genetics of schizophrenia: past, present and future. J Biosci 2002;27:35–52.Google Scholar
64Jerling, M, Merle, Y, Mentre, F, Mallet, A.Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997;44:447–453.Google Scholar